Overview
Gastroduodenitis involves inflammation of the stomach and duodenum, often associated with Helicobacter pylori infection, contributing to symptoms like dyspepsia and peptic ulcer disease 1.Diagnosis
Clinical Presentation: Symptoms include epigastric pain, nausea, vomiting, and sometimes weight loss.
Laboratory Tests: Serum cholinesterase activity may be low, particularly in pediatric patients with peptic ulcer disease, potentially indicating altered parasympathetic function 2.
Endoscopy: Essential for visualizing mucosal changes and obtaining biopsies for histological assessment and H. pylori testing.
Urease Breath Test/Stool Antigen Test: Non-invasive methods for detecting H. pylori infection.
Histology: Biopsy examination for inflammation and specific signs of H. pylori infection.
Culture and Sensitivity: Confirms H. pylori presence and guides antibiotic therapy.
Grading: Severity often graded based on endoscopic findings and histological inflammation scores.Management
First-Line Treatment: Triple therapy (proton pump inhibitor + two antibiotics, e.g., amoxicillin, clarithromycin) for H. pylori eradication 1.
Adjunctive Treatments: Symptomatic relief with proton pump inhibitors (PPIs) for acid suppression.
Follow-Up: Confirm eradication post-treatment via urea breath test or stool antigen test 1.Special Populations
Pediatrics: Serum cholinesterase activity monitoring may provide insights into disease severity and parasympathetic function 2.
Pregnancy: Management focuses on symptomatic relief with PPIs; H. pylori eradication therapy should be individualized considering risks and benefits 1.
Elderly: Increased vigilance for complications; tailored antibiotic regimens considering comorbidities and drug interactions 1.
Comorbidities: Consider potential drug interactions and adjust treatment plans accordingly, especially in patients with renal or hepatic impairment 1.Key Recommendations
Eradicate H. pylori in patients diagnosed with gastroduodenitis to prevent recurrence and complications (Evidence: Strong 1).
Monitor serum cholinesterase activity in pediatric patients with gastroduodenitis or peptic ulcers to assess disease severity (Evidence: Moderate 2).
Use proton pump inhibitors for symptomatic relief and acid suppression in the management of gastroduodenitis (Evidence: Expert opinion 1).References
1 Egan BJ, O'Morain CA. A historical perspective of Helicobacter gastroduodenitis and its complications. Best practice & research. Clinical gastroenterology 2007. link
2 Szewczyk L, Szczepanowska H, Zbarańska S. Serum cholinesterase activity in children with gastroduodenitis or peptic ulcer disease. Roczniki Akademii Medycznej w Bialymstoku (1995) 1997. link